ERBB2 and cancer: In patients with an ECOG ≤2, the European and French guidelines29, 30 recommend doublet or triplet first‐line treatment with FU, platinum, taxane or irinotecan for HER2 negative cancer, and with FU, platinum and trastuzumab for HER2 positive cancer.